Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-arm, Exploratory Study on the Efficacy and Safety of Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Patients With Neuroendocrine Bladder Carcinoma

NCT06091124 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT06091124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06091124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-arm, Exploratory Study on the Efficacy and Safety of Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Patients With Neuroendocrine Bladder Carcinoma
Lead sponsor
RenJi Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
November 16, 2023
Completion date
December 31, 2027
Enrollment
22 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, neuroendocrine carcinoma of the bladder